Executive Director, Alliance Development, U.S. Policy & Government Affairs (USPGA) at Bristol-Myers Squibb

Washington, District of Columbia, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Healthcare, Government AffairsIndustries

Requirements

Extensive understanding of U.S. government affairs, particularly Congress, the Executive Branch, and State Legislatures
Experience working with advocacy and patient groups making and influencing policy
Deep and pre-existing networks in the beltway trade association, patient group, and think tank communities
Strong knowledge of current public policies impacting the U.S. biopharmaceutical industry

Responsibilities

Serve as a member of the USPGA leadership team and drive achievement of high impact organization approved goals
Lead and manage a team of approximately 11 federal and state alliance development staff in Washington, DC and throughout the country
Develop, implement and execute comprehensive alliance and advocacy strategies that reflect business priorities that support key business objectives for inline and pipeline products
Position BMS as the key resource to inform stakeholders (patient groups, provider groups, think tanks, trade associations) in the development of policies and messaging on issues of importance and relevance
Actively participate in strategic planning with key trade associations, patient groups, think tanks, coalitions and other key partners to ensure political and policy alignment with BMS business priorities
Build, maintain and expand relationships with relevant leaders at key third-party groups
Develop plan to engage corporate executives more visibly with key third parties

Skills

Alliance Development

Government Affairs

Policy Strategy

Stakeholder Engagement

Federal Policy

State Policy

Healthcare Policy

Team Leadership

Strategic Partnerships

Patient Advocacy

Trade Associations

Thought Leadership

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free